(PDF) P2.13-30 High-Dose Icotinib in Advanced Non-Small

P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer With EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1425

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology

Respiratory Medicine

English

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients With Non-Small Cell Lung Cancer Who Received Icotinib Progress

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-29 IL-22 Confers Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-17 Non-Small Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder.

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Cancer Research

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English